Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma

2012 ◽  
Vol 413 (1-2) ◽  
pp. 143-149 ◽  
Author(s):  
Lutz Götze ◽  
Axel Hegele ◽  
Stephan Klaus Metzelder ◽  
Harald Renz ◽  
Wolfgang Andreas Nockher
Keyword(s):  
Tyrosine Kinase ◽  
Simultaneous Determination ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
Clinical Application ◽  
Kinase Inhibitors

scholarly journals Ultra High Performance Liquid Chromatography Method for the Determination of Two Recently FDA Approved TKIs in Human Plasma Using Diode Array Detection

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Marwa Fouad ◽  
Maxime Helvenstein ◽  
Bertrand Blankert
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
High Performance ◽  
Kinase Inhibitors ◽  
Therapeutic Window ◽  
Therapeutic Drug

Generally, tyrosine kinase inhibitors have narrow therapeutic window and large interpatient variability compared to intrapatient variability. In order to support its therapeutic drug monitoring, two fast and accurate methods were developed for the determination of recently FDA approved anticancer tyrosine kinase inhibitors, afatinib and ibrutinib, in human plasma using ultra high performance liquid chromatography coupled to PDA detection. Diclofenac sodium was used as internal standard. The chromatographic separation was achieved on an Acquity UPLC BEH C18 analytical column using a mobile phase combining ammonium formate buffer and acetonitrile at a constant flow rate of 0.4 mL/min using gradient elution mode. AµSPE (solid phase extraction) procedure, using Oasis MCXµElution plates, was processed and it gave satisfying and reproducible results in terms of extraction yields. Additionally, the methods were successfully validated using the accuracy profiles approach (β= 95% and acceptance limits = ±15%) over the ranges 5–250 ng/mL for afatinib and from 5 to 400 ng/mL for ibrutinib in human plasma.

Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS

2011 ◽  
Vol 412 (11-12) ◽  
pp. 1060-1067 ◽  
Author(s):  
Stéphane Bouchet ◽  
Emmanuelle Chauzit ◽  
Dominique Ducint ◽  
Nadège Castaing ◽  
Mireille Canal-Raffin ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Solid Phase Extraction ◽  
Simultaneous Determination ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Solid Phase ◽  
Phase Extraction

Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma

2016 ◽  
Vol 38 (4) ◽  
pp. 516-524 ◽  
Author(s):  
Ivo Vrobel ◽  
Hana Janečková ◽  
Edgar Faber ◽  
Kateřina Bouchalová ◽  
Kateřina Mičová ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Human Plasma ◽  
Tyrosine Kinase Inhibitors ◽  
Kinase Inhibitors ◽  
Online Spe

Validation and clinical application of an LC-ESI-MS/MS method for simultaneous determination of tolmetin and MED5, the metabolites of amtolmetin guacil in human plasma

2010 ◽  
Vol 24 (10) ◽  
pp. 1100-1107 ◽  
Author(s):  
Kishore Kumar Hotha ◽  
D. Vijaya Bharathi ◽  
S. Sirish Kumar ◽  
Y. Narsimha Reddy ◽  
Pankaj Chatki ◽  
...  
Keyword(s):  
Simultaneous Determination ◽  
Human Plasma ◽  
Clinical Application ◽  
Esi Ms
Sign in / Sign up

Export Citation Format

Share Document